Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study

Stopped Pause on clinical trial enrollment due to grant funding cuts after COVID-19

Conditions

• HIV
• Human Immunodeficiency Virus

Interventions

• DRUG: Euphorbia kansui extract powder prepared as tea

Sponsor

University of California, San Francisco

Collaborators

• [object Object]
• [object Object]